HORIZON (OP-106): melflufen plus dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibody (mAb) - final primary analysis

Autores: Richardson, P. G.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Rodríguez Otero, Paula; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; Touzeau, C.; Alegre, A.; Paner, A.; Maisel, C.; Mazumder, A.; Raptis, A.; Puig, N.; Harmenberg, J.; Byrne, C.; Thuresson, S.; Obermuller, J.; Mateos, M. V.